Precigen, Inc. Reports Q1 2025 Financial Results

Precigen, Inc. ( (PGEN) ) has released its Q1 earnings. Here is a breakdown of the information Precigen, Inc. presented to its investors.

Precigen, Inc. is a biopharmaceutical company focused on developing innovative gene and cell therapies, primarily in the fields of immuno-oncology, autoimmune disorders, and infectious diseases. The company recently announced its first quarter 2025 financial results and business updates, highlighting significant progress in its PRGN-2012 program, a potential first-of-its-kind treatment for recurrent respiratory papillomatosis (RRP). The company’s biologics license application for PRGN-2012 is under priority review by the FDA, with a decision expected by August 27, 2025.

In the first quarter of 2025, Precigen reported cash, cash equivalents, and investments totaling $81 million, which are expected to fund operations into 2026. The company also noted a 26% increase in total revenues compared to the same period in 2024, driven by higher product and service sales. However, the net loss for the quarter widened to $54.2 million, primarily due to a significant increase in the fair value of warrant liabilities.

Precigen’s PRGN-2012 program showed promising results in clinical trials, with a high percentage of patients achieving complete response and a reduction in surgical interventions. The company is preparing for a potential commercial launch in 2025, collaborating with EVERSANA to develop a targeted go-to-market strategy. Additionally, the company is advancing its PRGN-2009 and PRGN-3006 programs, targeting HPV-associated cancers and acute myeloid leukemia, respectively.

Looking ahead, Precigen remains focused on advancing its pipeline and preparing for the potential approval and commercialization of PRGN-2012. The company is optimistic about its future prospects, with ongoing clinical trials and strategic partnerships aimed at addressing unmet medical needs in its core therapeutic areas.